ST. PAUL, Minn., Sep 20, 2010 (BUSINESS WIRE) -- St. Jude Medical, Inc. /quotes/comstock/13*!stj/quotes/nls/stj (STJ 37.09, +0.04, +0.11%) , a global medical device company, today announced European CE Mark approval of its new Athena(TM) programmer, a deep brain stimulation (DBS) therapy management system. This next-generation platform offers clinicians a powerful yet easy-to-use interface that enables them to set or adjust therapeutic parameters to optimize patient results. Additionally, the system has the most comprehensive data management capacity on the market, which will aid clinicians in the organization and storage of patient information.
The Athena programmer is a notebook-based PC that can be utilized through an interactive touch screen or keyboard according to the clinician’s preference. The system features include:
-- Largest and only full-color touch screen measuring 22.6 cm, which allows users to see all leads and programming information at one time;
-- Patient database feature that can hold up to 200,000 patient records, providing a full history of programming sessions for every patient;
-- Data export capability that permits the user to export data for analysis, printing and emailing;
-- Clinician notes section that provides a convenient means to add information about each programming session and that can easily be accessed in subsequent sessions
“Because deep brain stimulation programming is often a complex and time-consuming process, we are pleased to provide physicians with this state-of-the-art programmer,” said Chris Chavez, president of the St. Jude Medical Neuromodulation Division. “The Athena programmer addresses several unmet needs and presents physicians with a unique, new option in programming and the management of deep brain stimulation devices to advance this therapy.”
The latest addition to the St. Jude Medical portfolio of DBS products, the Athena programmer can be used to program the Libra(TM), LibraXP(TM), and Brio(TM) DBS systems. These deep brain stimulation systems are approved for use in European Union countries and Australia. The Athena programmer is currently approved in European Union countries and is in the submission process for additional markets. Deep brain stimulation is used to treat the symptoms of Parkinson’s disease, a neurological disorder that progressively diminishes a person’s control over his or her movements and speech. Parkinson’s disease affects an estimated 6.3 million people worldwide, according to the European Parkinson’s Disease Association.
Three decades of leading edge neurostimulation technology
For more than 30 years, the St. Jude Medical Neuromodulation Division has developed new technologies to manage chronic pain and other neurological disorders. Today more than 75,000 patients in 40 countries have been implanted with St. Jude Medical neurostimulation systems.
About St. Jude Medical
St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. St. Jude Medical is headquartered in St. Paul, Minn. and has four major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. For more information, please visit sjm.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended April 3, 2010. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
